Banti's syndrome mainly affects the spleen, leading to the early destruction of blood cells and causing pancytopenia as a result of excessive spleen activity. Key features of this condition include splenomegaly, unexplained portal hypertension, and anaemia without other blood disorders. It was first detailed by Guido Banti, a professor of pathological anatomy in Florence, Italy, in 1894, as a form of congestive splenomegaly without any blockage in the intrahepatic or extrahepatic veins. Banti described it as a slowly progressing disease that inevitably leads to death. In India, it is referred to as non-cirrhotic portal hypertension (NCPH), while in Japan, it is known as idiopathic portal hypertension (IPH).

Epidemiology

Banti syndrome affects both men and women equally. It's commonly observed in areas of India, Pakistan, and Japan, but is rarely seen in Western countries. Increased arsenic levels in drinking water in various countries might be influencing these regional differences in the prevalence. Research has shown a higher number of cases in males in India, while in Western countries and Japan, females are more commonly affected. The condition tends to impact younger individuals, typically between the ages of 25 and 35.

Idiopathic portal hypertension

This syndrome is associated with increased portal and splenic pressures, leading to portal hypertension of unknown cause. Portal hypertension is characterised by elevated pressures in the portal venous system, which exceed those in the inferior vena cava by more than 5 mm Hg. This condition often results in the dilation and thickening of the portal vein walls, oesophageal varices, and significant splenomegaly, typically more than 10 cm below the left rib margin. Potential causes for the obstruction and increased blood pressure in the portal, hepatic, or splenic veins may include congenital abnormalities, blood clots, or other conditions causing inflammation and vascular obstruction. Other factors such as coagulation disorders, high arsenic intake, and hepatitis B infection have been associated with Banti’s syndrome. Additionally, long-term use of azathioprine in kidney transplant patients has been associated with the condition. In Japan, idiopathic portal hypertension is often connected with autoimmune diseases like systemic lupus erythematosus, progressive systemic sclerosis, thyroiditis, or mixed connective tissue disease.

Splenomegaly

In Banti's syndrome, the spleen is the main organ affected, leading to its persistent and congestive enlargement. This occurs due to blocked blood flow in certain veins and elevated blood pressure in the hepatic, portal, or splenic veins.

Anaemia

Normally, red blood cells (RBCs) have a lifespan of around 120 days, after which they are broken down in the spleen. In Banti’s syndrome, RBCs are destroyed prematurely, leading to anaemia, which may be exacerbated by bleeding from gastro-oesophageal varices. Patients experience fatigue and weakness due to this.

Thrombocytopenia

In Banti’s syndrome, the spleen sequesters about 90% of the total platelets, reducing their circulation in the blood. While platelet production and lifespan remain normal, the spleen’s abnormal function results in a significant decrease in circulating platelets. This manifests as bleeding or bruising.

Leukopenia

This condition occurs due to the destruction of white blood cells or increased sequestration within the spleen, thereby increasing the risk of infections.

Jaundice

Jaundice can also occur in Banti's syndrome, and it presents as yellowing of the skin and eyes.

Variceal bleeding

Portal hypertension can cause the development of varices (enlarged veins) in the oesophagus or stomach, which are susceptible to rupture and result in severe, life-threatening bleeding. Individuals with Banti’s syndrome often exhibit bleeding from gastro-oesophageal varices without the presence of ascites, jaundice, or other indicators of liver failure. The outlook is generally favourable. Treatment typically involves sclerotherapy or portocaval anastomoses. Immediate treatment may involve vasoconstrictor medications or other therapies for portal hypertension, while recurrent episodes might require a surgical shunt to alter blood flow.

Ascites: ascites

When pressure in the portal vein rises, fluid can accumulate in the abdominal cavity, causing ascites. This condition can lead to discomfort, abdominal swelling, and trouble breathing. Ascites is not commonly seen in cases of Banti's syndrome.

Diagnosis and treatment

To diagnose Banti's syndrome, a comprehensive clinical assessment combined with specialised tests, including advanced imaging techniques like splenic venography and magnetic resonance imaging (MRI), is often required. MRI employs a magnetic field and radio waves to create detailed cross-sectional images of specific body areas.

The treatment for Banti's syndrome depends on its underlying cause. If factors such as arsenic or azathioprine are identified, eliminating exposure to these substances are essential. The primary concern in this condition is bleeding from enlarged blood vessels in the oesophagus or stomach, known as varices.

Active bleeding can be managed with medications that constrict blood vessels or other treatments for portal hypertension. In cases of recurrent bleeding, a surgical shunt might be necessary to redirect blood flow. Patients with portal hypertension are prescribed beta-blockers to help prevent complications. In 1988, the FDA approved Ethamolin as an orphan drug for managing bleeding oesophageal varices.

Management and prognosis

The primary focus in managing Banti's syndrome involves addressing gastrointestinal bleeding due to portal hypertension and treating hypersplenism. Variceal ligation and endoscopic sclerotherapy both provide effective treatment for acute gastrointestinal bleeding, achieving success rates of around 95%. Even so, variceal ligation has a recurrence rate of about 20%, while sclerotherapy has a significantly lower recurrence rate of around 3%. In certain instances, surgical shunt procedures might be required as a last resort.

For patients experiencing symptomatic hypersplenism, severe anaemia requiring frequent blood transfusions, or recurrent splenic infarctions, surgical intervention may be needed. Both open and laparoscopic splenectomy options are available. The open technique involves mobilising the spleen by cutting its lateral and superior pole attachments or making an incision in the left subcostal or midline area.

The outlook for Banti's syndrome is usually favourable, with a reported 100% survival rate over five years after successful variceal ligation. A case study in the International Journal of Case Reports in Surgery highlighted a patient's excellent recovery after surgery. The patient, who underwent splenectomy due to severe anaemia and significant splenomegaly, showed a rapid improvement in platelet counts and a steady increase in haemoglobin levels during the follow-up.

Summary

Banti's Syndrome is a condition that impacts the spleen, leading to the premature breakdown of blood cells and resulting in pancytopenia as a consequence of excessive spleen activity. First identified by Guido Banti in 1894, it is characterised by an enlarged spleen, anaemia without other haematological issues, and unexplained portal hypertension. The syndrome is more common in Japan, India, and Pakistan compared to Western countries. Associated complications include portal hypertension, splenomegaly, anaemia, thrombocytopenia, leukopenia, and jaundice. Though rare, Banti's syndrome can lead to serious health issues if not treated. Early diagnosis and proper management are vital to control the condition and avoid complications. Patients can manage their symptoms and maintain a good quality of life with a healthy lifestyle and regular medical care.

FAQs

Is banti’s syndrome genetic?

There is no known genetic link to Banti's syndrome. Studies show a male-to-female ratio of about 1:1.5, with onset ranging from 10 to 59 years and an average age of 30 years in research from India.

Does covid-19 cause banti’s syndrome?

There is no proof that COVID-19 directly leads to Banti's syndrome. A recent case involved a 32-year-old male who initially presented with haematemesis and later developed symptoms consistent with Banti's syndrome, including ascites, splenomegaly, and bleeding varices. His COVID-19 serology was positive, but it's unclear how COVID-19 might lead to Banti's syndrome. COVID-19 is known to cause hypercoagulability, which might contribute to thrombosis in the portal veins, but further research is needed to understand this relationship better.

What is the prognosis of banti’s syndrome?

The prognosis for Banti's Syndrome is generally positive, with a 5-year survival rate of 100% reported following successful treatment of variceal bleeding.

How rare is INCPH in western countries?

INCPH (idiopathic noncirrhotic portal hypertension) is much less common in Western countries than in developing regions. It is more commonly seen in socioeconomically disadvantaged populations and was notably prevalent in India in the 1980s, but has since declined from 23% to 5.6% of portal hypertension cases. In Japan, the incidence was 0.75 per 100,000 people per year in 1985, with more recent surveys in 1998 and 2004 documenting 322 and 229 patients, respectively. In the West, INCPH accounts for only 3%–5% of portal hypertension cases.

This higher prevalence in developing regions may be linked to higher rates of gut bacterial infections and subsequent portal vein obstructions. Better hygiene and improved living standards are probably factors that have led to the decrease in INCPH cases in countries like India and Japan. The rarity of INCPH in Western countries might also be due to its overlap with liver cirrhosis, which is more frequently diagnosed and could lead to INCPH being underreported. The absence of a comprehensive national database further complicates accurate prevalence estimates of INCPH.